ERK Cancer Research Results

ERK, ERK signaling: Click to Expand ⟱
Source:
Type:
MAPK3 (ERK1)
ERK proteins are kinases that activate other proteins by adding a phosphate group. An overactivation of these proteins causes the cell cycle to stop.
The extracellular signal-regulated kinase (ERK) signaling pathway is a crucial component of the mitogen-activated protein kinase (MAPK) signaling cascade, which plays a significant role in regulating various cellular processes, including proliferation, differentiation, and survival. high levels of phosphorylated ERK (p-ERK) in tumor samples may indicate active ERK signaling and could correlate with aggressive tumor behavior

EEk singaling is frequently activated and is often associated with aggressive tumor behavior, treatment resistance, and poor outcomes.
Scientific Papers found: Click to Expand⟱
324- AgNPs,  CPT,    Silver Nanoparticles Potentiates Cytotoxicity and Apoptotic Potential of Camptothecin in Human Cervical Cancer Cells
- in-vitro, Cerv, HeLa
ROS↑, Casp3↑, Casp9↑, Casp6↑, GSH↓, SOD↓, GPx↓, MMP↓, P53↑, P21↑, Cyt‑c↑, BID↑, BAX↑, Bcl-2↓, Bcl-xL↓, Akt↓, Raf↓, ERK↓, MAP2K1/MEK1↓, JNK↑, p38↑,
309- AgNPs,    Interference of silver, gold, and iron oxide nanoparticles on epidermal growth factor signal transduction in epithelial cells
- in-vitro, NA, A431
ROS↑, Akt↓, p‑ERK↓,
382- AgNPs,    Investigation the apoptotic effect of silver nanoparticles (Ag-NPs) on MDA-MB 231 breast cancer epithelial cells via signaling pathways
- in-vitro, BC, MDA-MB-231
Apoptosis↑, BAX↑, Bcl-2↓, P53↑, PTEN↑, hTERT/TERT↓, p‑ERK↓, cycD1/CCND1↓,
2288- AgNPs,    Silver Nanoparticle-Mediated Cellular Responses in Various Cell Lines: An in Vitro Model
- Review, Var, NA
*ROS↑, Akt↓, ERK↓, DNAdam↑, Ca+2↑, ROS↑, MMP↓, Cyt‑c↑, TumCCA↑, DNAdam↑, Apoptosis↑, P53↑, p‑ERK↑, ER Stress↑, cl‑ATF6↑, GRP78/BiP↑, CHOP↑, UPR↑,
2662- AL,    Allicin inhibits tubular epithelial-myofibroblast transdifferentiation under high glucose conditions in vitro
- in-vitro, Nor, HK-2
*α-SMA↓, *Vim↓, *COL1↓, *E-cadherin↑, *TGF-β1↓, *p‑ERK↓, *EMT↓,
253- AL,    Allicin inhibits invasion and migration of breast cancer cells through the suppression of VCAM-1: Regulation of association between p65 and ER-α
- in-vitro, BC, MDA-MB-231
TumCMig↓, ERK↓, VCAM-1↓, NF-kB↓,
295- ALA,    α-Lipoic acid suppresses migration and invasion via downregulation of cell surface β1-integrin expression in bladder cancer cells
- in-vitro, Bladder, T24/HTB-9
ITGB1↓, TumCMig↓, ERK↓, Akt↓,
262- ALA,    Lipoic acid decreases breast cancer cell proliferation by inhibiting IGF-1R via furin downregulation
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
TumCP↓, Akt↓, ERK↓, IGF-1R↓, Furin↓, Ki-67↓, AMPK↑, mTOR↓,
1253- aLinA,    The Antitumor Effects of α-Linolenic Acid
- Review, NA, NA
PPARγ↑, COX2↓, E6↓, E7↓, P53↑, p‑ERK↓, p38↓, lipid-P↑, ROS⇅, MPT↑, MMP↓, Cyt‑c↑, Casp↑, iNOS↓, NO↓, Casp3↑, Bcl-2↓, Hif1a↓, FASN↓, CRP↓, IL6↓, IL1β↓, IFN-γ↓, TNF-α↓, Twist↓, VEGF↓, MMP2↓, MMP9↓,
1093- And,    Andrographolide attenuates epithelial‐mesenchymal transition induced by TGF‐β1 in alveolar epithelial cells
- in-vitro, Lung, A549
TGF-β↓, TumCMig↓, MMP2↓, MMP9↓, ECM/TCF↓, p‑SMAD2↓, p‑SMAD3↓, SMAD4↓, p‑ERK↓, ROS↓, NOX4↓, SOD2↑, SIRT1↑, FOXO3↑,
1545- Api,    The Potential Role of Apigenin in Cancer Prevention and Treatment
- Review, NA, NA
TNF-α↓, IL6↓, IL1α↓, P53↑, Bcl-xL↓, Bcl-2↓, BAX↑, Hif1a↓, VEGF↓, TumCCA↑, DNAdam↑, Apoptosis↑, CycB/CCNB1↓, cycA1/CCNA1↓, CDK1↓, PI3K↓, Akt↓, mTOR↓, IKKα↓, ERK↓, p‑Akt↓, p‑P70S6K↓, p‑S6↓, p‑ERK↓, p‑P90RSK↑, STAT3↓, MMP2↓, MMP9↓, TumCP↓, TumCMig↓, TumCI↓, Wnt/(β-catenin)↓,
1539- Api,  LT,    Dietary flavones counteract phorbol 12-myristate 13-acetate-induced SREBP-2 processing in hepatic cells
- in-vitro, Liver, HepG2
SREBP2↓, eff↑, p‑MEK↓, p‑ERK↓,
2633- Api,    Apigenin induces ROS-dependent apoptosis and ER stress in human endometriosis cells
- in-vitro, EC, NA
TumCP↓, TumCCA↑, MMP↓, Ca+2↑, BAX↑, Cyt‑c↑, ROS↑, lipid-P↑, ER Stress↑, UPR↑, p‑ERK↓, ERK↓, JNK↑,
2640- Api,    Apigenin: A Promising Molecule for Cancer Prevention
- Review, Var, NA
chemoPv↑, ITGB4↓, TumCI↓, TumMeta↓, Akt↓, ERK↓, p‑JNK↓, *Inflam↓, *PKCδ↓, *MAPK↓, EGFR↓, CK2↓, TumCCA↑, CDK1↓, P53↓, P21↑, Bax:Bcl2↑, Cyt‑c↑, APAF1↑, Casp↑, cl‑PARP↑, VEGF↓, Hif1a↓, IGF-1↓, IGFBP3↑, E-cadherin↑, β-catenin/ZEB1↓, HSPs↓, Telomerase↓, FASN↓, MMPs↓, HER2/EBBR2↓, CK2↓, eff↑, AntiAg↑, eff↑, FAK↓, ROS↑, Bcl-2↓, Cyt‑c↑, cl‑Casp3↑, cl‑Casp7↑, cl‑Casp8↑, cl‑Casp9↑, cl‑IAP2↑, AR↓, PSA↓, p‑pRB↓, p‑GSK‐3β↓, CDK4↓, ChemoSen↑, Ca+2↑, cal2↑,
243- Api,    Apigenin Attenuates Melanoma Cell Migration by Inducing Anoikis through Integrin and Focal Adhesion Kinase Inhibition
- in-vitro, Melanoma, A375 - in-vitro, Melanoma, A2058
p‑FAK↓, ERK↓, Casp3↑, PARP↑, ITGA5↓,
171- Api,    Apigenin in cancer therapy: anti-cancer effects and mechanisms of action
- Review, Var, NA
PI3K/Akt↓, NF-kB↓, CK2↓, FOXO↓, MAPK↝, ERK↓, p‑JAK↓, Wnt/(β-catenin)↓, ROS↑, CDC25↓, p‑STAT↓, DNAdam↑,
242- Api,    Apigenin inhibits proliferation and invasion, and induces apoptosis and cell cycle arrest in human melanoma cells
- in-vitro, Melanoma, A375 - in-vitro, Melanoma, C8161
ERK↓, PI3k/Akt/mTOR↓, Casp3↑, PARP↑, p‑mTOR↓, p‑Akt↓,
3391- ART/DHA,    Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug
- Review, Var, NA
TumCP↓, TumMeta↓, angioG↓, TumVol↓, BioAv↓, Half-Life↓, BioAv↑, eff↑, eff↓, ROS↑, selectivity↑, TumCCA↑, survivin↓, BAX↑, Casp3↓, Casp8↑, Casp9↑, CDC25↓, CycB/CCNB1↓, NF-kB↓, cycD1/CCND1↓, cycE/CCNE↓, E2Fs↓, P21↑, p27↑, ADP:ATP↑, MDM2↓, VEGF↓, IL8↓, COX2↓, MMP9↓, ER Stress↓, cMyc↓, GRP78/BiP↑, DNAdam↑, AP-1↓, MMP2↓, PKCδ↓, Raf↓, ERK↓, JNK↓, PCNA↓, CDK2↓, CDK4↓, TOP2↓, uPA↓, MMP7↓, TIMP2↑, Cdc42↑, E-cadherin↑,
3392- ART/DHA,    Artemisinin inhibits inflammatory response via regulating NF-κB and MAPK signaling pathways
- in-vitro, Nor, Hep3B - in-vivo, NA, NA
*Inflam↓, *NF-kB↓, *ROS↓, *p‑p38↓, *p‑ERK↓,
1148- ART/DHA,    Artemisinin inhibits extracellular matrix metalloproteinase inducer (EMMPRIN) and matrix metalloproteinase-9 expression via a protein kinase Cδ/p38/extracellular signal-regulated kinase pathway in phorbol myristate acetate-induced THP-1 macrophages
- in-vitro, AML, THP1
MMP9↓, EMMPRIN↓, p‑PKCδ↓, p‑JNK↓, p‑p38↓, p‑ERK↓,
573- ART/DHA,    Artesunate suppresses tumor growth and induces apoptosis through the modulation of multiple oncogenic cascades in a chronic myeloid leukemia xenograft mouse model
- vitro+vivo, NA, NA
p‑p38↓, p‑ERK↓, p‑CREB↓, p‑Chk2↓, p‑STAT5↓, p‑RSK↓, SOCS1↑, Apoptosis↑, Casp3↑,
556- ART/DHA,    Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing
- Review, NA, NA
IL6↓, IL1↓, TNF-α↓, TGF-β↓, NF-kB↓, MIP2↓, PGE2↓, NO↓, Hif1a↓, KDR/FLK-1↓, VEGF↓, MMP2↓, TIMP2↑, ITGB1↑, NCAM↑, p‑ATM↑, p‑ATR↑, p‑CHK1↑, p‑Chk2↑, Wnt/(β-catenin)↓, PI3K↓, Akt↓, ERK↓, cMyc↓, mTOR↓, survivin↓, cMET↓, EGFR↓, cycD1/CCND1↓, cycE1↓, CDK4/6↓, p16↑, p27↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, oncosis↑, TumCCA↑, ROS↑, DNAdam↑, RAD51↓, HR↓,
1026- ART/DHA,    Artemisinin improves the efficiency of anti-PD-L1 therapy in T-cell lymphoma
Ferroptosis↑, ROS↑, ERK↓, PD-L1↓,
3162- Ash,    Molecular insights into cancer therapeutic effects of the dietary medicinal phytochemical withaferin A
- Review, Var, NA
lipid-P↓, SOD↑, GPx↑, P53↑, Bcl-2↑, E6↓, E7↓, pRB↑, CycB/CCNB1↑, CDC2↑, P21↑, PCNA↓, ALDH1A1↓, Vim↓, Glycolysis↓, cMyc↓, BAX↑, NF-kB↓, Casp3↑, CHOP↑, DR5↑, ERK↓, Wnt↓, β-catenin/ZEB1↓, Akt↓, HSP90↓,
5389- AsP,  Tras,    ASCORBYL PALMITATE ENHANCES ANTI-PROLIFERATIVE EFFECT OF TRASTUZUMAB IN HER2-POSITIVE BREAST CANCER CELLS
tumCV↓, eff↑, P53↑, BAX↑, Casp3↑, Casp8↑, Bcl-2↓, Apoptosis↑, p‑p38↓, ERK↓, PI3K↓,
4815- ASTX,    The Promising Effects of Astaxanthin on Lung Diseases
- Review, Var, NA
Dose↑, *BioAv↝, *BioAv↝, *antiOx↑, *NRF2↑, *ERK↓,
4812- ASTX,    Astaxanthin suppresses the metastasis of colon cancer by inhibiting the MYC-mediated downregulation of microRNA-29a-3p and microRNA-200a
- in-vitro, CRC, HCT116
miR-29b↑, miR-200b↑, MMP2↓, Zeb1↓, EMT↓, Apoptosis↑, ERK↓, MAPK↓, PI3K↓, Akt↓, MMPs↓, TumMeta↓,
4809- ASTX,    Astaxanthin Inhibits Proliferation of Human Gastric Cancer Cell Lines by Interrupting Cell Cycle Progression
- in-vitro, GC, AGS - in-vitro, GC, MKN45
tumCV↓, TumCP↓, TumCCA↑, p‑ERK↓, p27↑, cycD1/CCND1↓, CDK4↓,
4805- ASTX,    Astaxanthin promotes apoptosis by suppressing growth signaling pathways in HT-29 colorectal cancer cells
- in-vitro, Colon, HT29
TumCP↓, Casp3↑, EGFR↓, HER2/EBBR2↓, ERK↓, Apoptosis↑,
5577- B-Gluc,    Lentinan progress in inflammatory diseases and tumor diseases
- Review, Var, NA - Review, IBD, NA
AntiTum↑, GutMicro↑, *Inflam↓, *TNF-α↓, *NF-kB↓, ChemoSen↑, OS↑, Imm↑, IL6↓, ERK↓, MAPK↓, *antiOx↑, eff↑,
874- B-Gluc,    Potential promising anticancer applications of β-glucans: a review
- Review, NA, NA
AntiCan↑, TumCG↓, BAX↑, Bcl-2↓, IFN-γ↑, PI3K/Akt↑, MAPK↑, NFAT↑, NF-kB↑, ROS↑, NK cell↑, TumCCA↑, ERK↓, Telomerase↓,
5505- Ba,    Baicalein inhibits the progression of thyroid cancer by suppressing the TPL2/MEK2/ERK2 pathway
- in-vitro, Thyroid, NA
ERK↓, PI3K↓, Akt↓, Apoptosis↑, TumAuto↑, NF-kB↑, MEK↓,
5502- Ba,    An overview of pharmacological activities of baicalin and its aglycone baicalein: New insights into molecular mechanisms and signaling pathways
- Review, Var, NA
*AntiCan↑, *antiOx↑, *hepatoP↑, *neuroP↑, *ROS↓, Ca+2↑, ROS↑, BAX↑, Casp3↑, Casp9↑, Cyt‑c↑, MMP↓, Mcl-1↓, PI3K↓, Akt↓, mTOR↓, BAD↓, ERK↓, MEK↓, DR5↑, Fas↑, TumMeta↓, EMT↓, SMAD4↓, TGF-β↓, MMP9↓, MMP2↓, HIF-1↓, 12LOX↓,
2606- Ba,    Baicalein: A review of its anti-cancer effects and mechanisms in Hepatocellular Carcinoma
- Review, HCC, NA
ChemoSen↑, TumCP↓, TumCCA↑, TumCMig↓, TumCI↓, MMPs↓, MAPK↓, TGF-β↓, ZFX↓, p‑MEK↓, ERK↓, MMP2↓, MMP9↓, uPA↓, TIMP1↓, TIMP2↓, NF-kB↓, p65↓, p‑IKKα↓, Fas↑, Casp2↑, Casp3↑, Casp8↑, Casp9↑, Bcl-xL↓, BAX↑, ER Stress↑, Ca+2↑, JNK↑, P53↑, ROS↑, H2O2↑, cMyc↓, CD24↓, 12LOX↓,
2597- Ba,    Baicalein – An Intriguing Therapeutic Phytochemical in Pancreatic Cancer
- Review, PC, NA
chemoP↑, ChemoSen↑, 12LOX?, Bcl-2↓, BAX↑, Mcl-1↓, ERK↓, Prx6↑, Dose↝, BioAv↓, eff↑,
2627- Ba,  Cisplatin,    Baicalein, a Bioflavonoid, Prevents Cisplatin-Induced Acute Kidney Injury by Up-Regulating Antioxidant Defenses and Down-Regulating the MAPKs and NF-κB Pathways
RenoP↑, *iNOS↑, *TNF-α↓, *IL6↓, *NF-kB↓, *MAPK↓, *ERK↓, *JNK↓, *antiOx↑, *NRF2↓, *HO-1↑, *Cyt‑c∅, *Casp3∅, *Casp9∅, *PARP∅,
5547- BBM,    Berbamine exerts anticancer effects on human colon cancer cells via induction of autophagy and apoptosis, inhibition of cell migration and MEK/ERK signalling pathway
- in-vitro, CRC, HT29
tumCV↓, selectivity↑, Casp3↑, Casp9↑, Bax:Bcl2↑, ATG5↑, Beclin-1↑, TumCP↓, MEK↓, ERK↓,
5549- BBM,    Synergistic Anticancer Effect of a Combination of Berbamine and Arcyriaflavin A against Glioblastoma Stem-like Cells
- in-vitro, GBM, NA
eff?, tumCV↓, TumCG↓, ROS↑, P53↑, CSCs↓, CD133↓, ALDH1A1↓, Nanog↓, SOX2↓, OCT4↓, CDK1↓, CaMKII ↓, STAT3↓, Akt↓, ERK↓,
1242- BBM,    Berbamine Exerts Anti-Inflammatory Effects via Inhibition of NF-κB and MAPK Signaling Pathways
- in-vivo, Nor, NA
*Macrophages↓, *Neut↓, *p‑NF-kB↓, *p‑MAPK↓, *p‑JNK↓, *p‑ERK↓,
2021- BBR,    Berberine: An Important Emphasis on Its Anticancer Effects through Modulation of Various Cell Signaling Pathways
- Review, NA, NA
*antiOx?, *Inflam↓, Apoptosis↑, TumCCA↑, BAX↑, eff↑, VEGF↓, PI3K↓, Akt↓, mTOR↓, Telomerase↓, β-catenin/ZEB1↓, Wnt↓, EGFR↓, AP-1↓, NF-kB↓, COX2↑, NRF2↓, RadioS↑, STAT3↓, ERK↓, AR↓, ROS↑, eff↑, selectivity↑, selectivity↑, BioAv↓, DNMT1↓, cMyc↓,
1395- BBR,    Analysis of the mechanism of berberine against stomach carcinoma based on network pharmacology and experimental validation
- in-vitro, GC, NA
Apoptosis↑, ROS↑, MMP↓, ATP↓, AMPK↑, TP53↑, p‑MAPK↓, p‑ERK↓,
1390- BBR,  Rad,    Berberine Inhibited Radioresistant Effects and Enhanced Anti-Tumor Effects in the Irradiated-Human Prostate Cancer Cells
- in-vitro, Pca, PC3
RadioS↑, Apoptosis↑, ROS↑, eff↑, BAX↑, Casp3↑, P53↑, p38↑, JNK↑, Bcl-2↓, ERK↓, HO-1↓,
1299- BBR,    Effects of Berberine and Its Derivatives on Cancer: A Systems Pharmacology Review
- Review, NA, NA
TumCCA↑, TP53↑, COX2↓, Bax:Bcl2↑, ROS↑, VEGFR2↓, Akt↓, ERK↓, MMP2↓, MMP9↓, IL8↑, P21↑, p27↑, E-cadherin↓, Fibronectin↓, cMyc↓,
2694- BBR,    Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells
- in-vitro, BC, NA
IL8↓, TumCI↓, EGFR↓, MEK↓, ERK↓, TGF-β1↓, VEGF↓,
2693- BBR,    Antitumor Effects of Berberine on Gliomas via Inactivation of Caspase-1-Mediated IL-1β and IL-18 Release
- in-vitro, GBM, U251 - in-vitro, GBM, U87MG
Casp1↓, ERK↓, IL1β↓, IL18↓, EMT↑,
2670- BBR,    Berberine: A Review of its Pharmacokinetics Properties and Therapeutic Potentials in Diverse Vascular Diseases
- Review, Var, NA
*Inflam↓, *antiOx↑, *Ca+2↓, *BioAv↓, *BioAv↑, *BioAv↑, *angioG↑, *MAPK↓, *AMPK↓, *NF-kB↓, VEGF↓, PI3K↓, Akt↓, MMP2↓, Bcl-2↓, ERK↓,
2674- BBR,    Berberine: A novel therapeutic strategy for cancer
- Review, Var, NA - Review, IBD, NA
Inflam↓, AntiCan↑, Apoptosis↑, TumAuto↑, TumCCA↑, TumMeta↓, TumCI↓, eff↑, eff↑, CD4+↓, TNF-α↓, IL1↓, BioAv↓, BioAv↓, other↓, AMPK↑, MAPK↓, NF-kB↓, IL6↓, MCP1↓, PGE2↓, COX2↓, *ROS↓, *antiOx↑, *GPx↑, *Catalase↑, AntiTum↑, TumCP↓, angioG↓, Fas↑, FasL↑, ROS↑, ATM↑, P53↑, RB1↑, Casp9↑, Casp8↑, Casp3↓, BAX↑, Bcl-2↓, Bcl-xL↓, IAP1↓, XIAP↓, survivin↓, MMP2↓, MMP9↓, CycB/CCNB1↓, CDC25↓, CDC25↓, Cyt‑c↑, MMP↓, RenoP↑, mTOR↓, MDM2↓, LC3II↑, ERK↓, COX2↓, MMP3↓, TGF-β↓, EMT↑, ROCK1↓, FAK↓, RAS↓, Rho↓, NF-kB↓, uPA↓, MMP1↓, MMP13↓, ChemoSen↑,
2686- BBR,    Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
- Review, Nor, NA
Inflam↓, IL6↓, MCP1↓, COX2↓, PGE2↓, MMP2↓, MMP9↓, DNAdam↑, eff↝, Telomerase↓, Bcl-2↓, AMPK↑, ROS↑, MMP↓, ATP↓, p‑mTORC1↓, p‑S6K↓, ERK↓, PI3K↓, PTEN↑, Akt↓, Raf↓, MEK↓, Dose↓, Dose↑, selectivity↑, TumCCA↑, eff↑, EGFR↓, Glycolysis↓, Dose?, p27↑, CDK2↓, CDK4↓, cycD1/CCND1↓, cycE/CCNE↓, Bax:Bcl2↑, Casp3↑, Casp9↑, VEGFR2↓, ChemoSen↑, eff↑, eff↑, PGE2↓, JAK2↓, STAT3↓, CXCR4↓, CCR7↓, uPA↓, CSCs↓, EMT↓, Diff↓, CD133↓, Nestin↓, n-MYC↓, NOTCH↓, SOX2↓, Hif1a↓, VEGF↓, RadioS↑,
5180- BBR,    Berberine Targets AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth
- in-vitro, NSCLC, NA
TumCMig↓, TumCP↓, Apoptosis↑, TFAP2A↓, hTERT/TERT↓, NF-kB↓, COX2↓, Hif1a↓, VEGF↓, Akt↓, p‑ERK↓, Cyt‑c↑, cl‑Casp↑, cl‑PARP↑, PI3K↓, Akt↓, Raf↓, MEK↓, ERK↓,
1473- BCA,  SFN,    An Insight on Synergistic Anti-cancer Efficacy of Biochanin A and Sulforaphane Combination Against Breast Cancer
- in-vitro, BC, MCF-7
eff↑, ROS↑, other↑, ERK↓, Apoptosis↑,

Showing Research Papers: 1 to 50 of 214
Page 1 of 5 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 214

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Ferroptosis↑, 2,   GPx↓, 1,   GPx↑, 1,   GSH↓, 1,   H2O2↑, 1,   HO-1↓, 1,   lipid-P↓, 1,   lipid-P↑, 2,   NOX4↓, 1,   NRF2↓, 1,   Prx6↑, 1,   ROS↓, 1,   ROS↑, 20,   ROS⇅, 1,   SOD↓, 1,   SOD↑, 1,   SOD2↑, 1,  

Mitochondria & Bioenergetics ⓘ

ADP:ATP↑, 1,   ATP↓, 2,   CDC2↑, 1,   CDC25↓, 4,   MEK↓, 6,   p‑MEK↓, 2,   MMP↓, 8,   MPT↑, 1,   Raf↓, 4,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

12LOX?, 1,   12LOX↓, 2,   AMPK↑, 4,   cMyc↓, 6,   p‑CREB↓, 1,   FASN↓, 2,   Glycolysis↓, 2,   PI3K/Akt↓, 1,   PI3K/Akt↑, 1,   PI3k/Akt/mTOR↓, 1,   PPARγ↑, 1,   p‑S6↓, 1,   p‑S6K↓, 1,   SIRT1↑, 1,   SREBP2↓, 1,  

Cell Death ⓘ

Akt↓, 19,   p‑Akt↓, 2,   APAF1↑, 1,   Apoptosis↑, 15,   BAD↓, 1,   BAX↑, 14,   Bax:Bcl2↑, 4,   Bcl-2↓, 12,   Bcl-2↑, 1,   Bcl-xL↓, 4,   BID↑, 1,   Casp↑, 2,   cl‑Casp↑, 1,   Casp1↓, 1,   Casp2↑, 1,   Casp3↓, 2,   Casp3↑, 13,   cl‑Casp3↑, 1,   Casp6↑, 1,   cl‑Casp7↑, 1,   Casp8↑, 4,   cl‑Casp8↑, 1,   Casp9↑, 7,   cl‑Casp9↑, 1,   p‑Chk2↓, 1,   p‑Chk2↑, 1,   CK2↓, 3,   Cyt‑c↑, 9,   DR5↑, 2,   Fas↑, 3,   FasL↑, 1,   Ferroptosis↑, 2,   hTERT/TERT↓, 2,   IAP1↓, 1,   cl‑IAP2↑, 1,   iNOS↓, 1,   JNK↓, 1,   JNK↑, 4,   p‑JNK↓, 2,   MAPK↓, 4,   MAPK↑, 1,   MAPK↝, 1,   p‑MAPK↓, 1,   Mcl-1↓, 2,   MDM2↓, 2,   oncosis↑, 1,   p27↑, 5,   p38↓, 1,   p38↑, 2,   p‑p38↓, 3,   p‑RSK↓, 1,   survivin↓, 3,   Telomerase↓, 4,  

Kinase & Signal Transduction ⓘ

CaMKII ↓, 1,   HER2/EBBR2↓, 2,  

Transcription & Epigenetics ⓘ

other↓, 1,   other↑, 1,   pRB↑, 1,   p‑pRB↓, 1,   tumCV↓, 4,  

Protein Folding & ER Stress ⓘ

cl‑ATF6↑, 1,   CHOP↑, 2,   ER Stress↓, 1,   ER Stress↑, 3,   GRP78/BiP↑, 2,   HSP90↓, 1,   HSPs↓, 1,   UPR↑, 2,  

Autophagy & Lysosomes ⓘ

ATG5↑, 1,   Beclin-1↑, 1,   LC3II↑, 1,   TumAuto↑, 3,  

DNA Damage & Repair ⓘ

ATM↑, 1,   p‑ATM↑, 1,   p‑ATR↑, 1,   p‑CHK1↑, 1,   DNAdam↑, 7,   DNMT1↓, 1,   HR↓, 1,   p16↑, 1,   P53↓, 1,   P53↑, 11,   PARP↑, 2,   cl‑PARP↑, 2,   PCNA↓, 2,   RAD51↓, 1,   TP53↑, 2,  

Cell Cycle & Senescence ⓘ

CDK1↓, 3,   CDK2↓, 2,   CDK4↓, 4,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 3,   CycB/CCNB1↑, 1,   cycD1/CCND1↓, 5,   cycE/CCNE↓, 2,   cycE1↓, 1,   E2Fs↓, 1,   P21↑, 5,   RB1↑, 1,   TFAP2A↓, 1,   TumCCA↑, 13,  

Proliferation, Differentiation & Cell State ⓘ

ALDH1A1↓, 2,   CD133↓, 2,   CD24↓, 1,   cMET↓, 1,   CSCs↓, 2,   Diff↓, 1,   EMT↓, 3,   EMT↑, 2,   ERK↓, 36,   p‑ERK↓, 12,   p‑ERK↑, 1,   FOXO↓, 1,   FOXO3↑, 1,   p‑GSK‐3β↓, 1,   IGF-1↓, 1,   IGF-1R↓, 1,   IGFBP3↑, 1,   MAP2K1/MEK1↓, 1,   mTOR↓, 6,   p‑mTOR↓, 1,   p‑mTORC1↓, 1,   n-MYC↓, 1,   Nanog↓, 1,   Nestin↓, 1,   NOTCH↓, 1,   OCT4↓, 1,   p‑P70S6K↓, 1,   p‑P90RSK↑, 1,   PI3K↓, 10,   PTEN↑, 2,   RAS↓, 1,   SOX2↓, 2,   p‑STAT↓, 1,   STAT3↓, 4,   p‑STAT5↓, 1,   TOP2↓, 1,   TumCG↓, 2,   Wnt↓, 2,   Wnt/(β-catenin)↓, 3,   ZFX↓, 1,  

Migration ⓘ

AntiAg↑, 1,   AP-1↓, 2,   Ca+2↑, 5,   cal2↑, 1,   Cdc42↑, 1,   CDK4/6↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 2,   EMMPRIN↓, 1,   FAK↓, 2,   p‑FAK↓, 1,   Fibronectin↓, 1,   Furin↓, 1,   ITGA5↓, 1,   ITGB1↓, 1,   ITGB1↑, 1,   ITGB4↓, 1,   Ki-67↓, 1,   miR-200b↑, 1,   miR-29b↑, 1,   MMP1↓, 1,   MMP13↓, 1,   MMP2↓, 12,   MMP3↓, 1,   MMP7↓, 1,   MMP9↓, 10,   MMPs↓, 3,   NCAM↑, 1,   NFAT↑, 1,   PKCδ↓, 1,   p‑PKCδ↓, 1,   Rho↓, 1,   ROCK1↓, 1,   p‑SMAD2↓, 1,   p‑SMAD3↓, 1,   SMAD4↓, 2,   TGF-β↓, 5,   TGF-β1↓, 1,   TIMP1↓, 1,   TIMP2↓, 1,   TIMP2↑, 2,   TumCI↓, 5,   TumCMig↓, 6,   TumCP↓, 10,   TumMeta↓, 5,   Twist↓, 1,   uPA↓, 4,   VCAM-1↓, 1,   Vim↓, 1,   Zeb1↓, 1,   β-catenin/ZEB1↓, 3,  

Angiogenesis & Vasculature ⓘ

angioG↓, 2,   ECM/TCF↓, 1,   EGFR↓, 6,   HIF-1↓, 1,   Hif1a↓, 6,   KDR/FLK-1↓, 1,   NO↓, 2,   VEGF↓, 10,   VEGFR2↓, 2,  

Immune & Inflammatory Signaling ⓘ

CCR7↓, 1,   CD4+↓, 1,   COX2↓, 7,   COX2↑, 1,   CRP↓, 1,   CXCR4↓, 1,   IFN-γ↓, 1,   IFN-γ↑, 1,   IKKα↓, 1,   p‑IKKα↓, 1,   IL1↓, 2,   IL18↓, 1,   IL1α↓, 1,   IL1β↓, 2,   IL6↓, 6,   IL8↓, 2,   IL8↑, 1,   Imm↑, 1,   Inflam↓, 2,   p‑JAK↓, 1,   JAK2↓, 1,   MCP1↓, 2,   MIP2↓, 1,   NF-kB↓, 10,   NF-kB↑, 2,   NK cell↑, 1,   p65↓, 1,   PD-L1↓, 1,   PGE2↓, 4,   PSA↓, 1,   SOCS1↑, 1,   TNF-α↓, 4,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 5,   BioAv↑, 1,   ChemoSen↑, 6,   Dose?, 1,   Dose↓, 1,   Dose↑, 2,   Dose↝, 1,   eff?, 1,   eff↓, 1,   eff↑, 16,   eff↝, 1,   Half-Life↓, 1,   RadioS↑, 3,   selectivity↑, 5,  

Clinical Biomarkers ⓘ

AR↓, 2,   CRP↓, 1,   E6↓, 2,   E7↓, 2,   EGFR↓, 6,   GutMicro↑, 1,   HER2/EBBR2↓, 2,   hTERT/TERT↓, 2,   IL6↓, 6,   Ki-67↓, 1,   PD-L1↓, 1,   PSA↓, 1,   TP53↑, 2,  

Functional Outcomes ⓘ

AntiCan↑, 2,   AntiTum↑, 2,   chemoP↑, 1,   chemoPv↑, 1,   OS↑, 1,   RenoP↑, 2,   TumVol↓, 1,  
Total Targets: 310

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx?, 1,   antiOx↑, 6,   Catalase↑, 1,   GPx↑, 1,   HO-1↑, 1,   NRF2↓, 1,   NRF2↑, 1,   ROS↓, 3,   ROS↑, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↓, 1,  

Cell Death ⓘ

Casp3∅, 1,   Casp9∅, 1,   Cyt‑c∅, 1,   iNOS↑, 1,   JNK↓, 1,   p‑JNK↓, 1,   MAPK↓, 3,   p‑MAPK↓, 1,   p‑p38↓, 1,  

DNA Damage & Repair ⓘ

PARP∅, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,   ERK↓, 2,   p‑ERK↓, 3,  

Migration ⓘ

Ca+2↓, 1,   COL1↓, 1,   E-cadherin↑, 1,   PKCδ↓, 1,   TGF-β1↓, 1,   Vim↓, 1,   α-SMA↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↑, 1,  

Immune & Inflammatory Signaling ⓘ

IL6↓, 1,   Inflam↓, 5,   Macrophages↓, 1,   Neut↓, 1,   NF-kB↓, 4,   p‑NF-kB↓, 1,   TNF-α↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 2,   BioAv↝, 2,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   hepatoP↑, 1,   neuroP↑, 1,  
Total Targets: 45

Scientific Paper Hit Count for: ERK, ERK signaling
12 Silymarin (Milk Thistle) silibinin
10 Berberine
10 Quercetin
9 Curcumin
9 EGCG (Epigallocatechin Gallate)
8 Fisetin
8 Shikonin
7 Apigenin (mainly Parsley)
7 Sulforaphane (mainly Broccoli)
7 Thymoquinone
6 Artemisinin
6 Caffeic acid
5 Luteolin
5 Baicalein
5 Lycopene
5 Resveratrol
4 Silver-NanoParticles
4 Astaxanthin
4 Carvacrol
4 Piperine
4 Emodin
4 Honokiol
4 Propolis -bee glue
3 Berbamine
3 Boswellia (frankincense)
3 Garcinol
3 Phenethyl isothiocyanate
3 Rosmarinic acid
3 Ursolic acid
2 Allicin (mainly Garlic)
2 Alpha-Lipoic-Acid
2 beta-glucans
2 Cisplatin
2 Radiotherapy/Radiation
2 Betulinic acid
2 Bromelain
2 Thymol-Thymus vulgaris
2 Chlorogenic acid
2 Chrysin
2 Deguelin
2 Paclitaxel
2 Magnetic Fields
2 Myricetin
2 Piperlongumine
2 Sanguinarine
2 Urolithin
2 Vitamin C (Ascorbic Acid)
2 Vitamin K2
1 Camptothecin
1 alpha Linolenic acid
1 Andrographis
1 Ashwagandha(Withaferin A)
1 Ascorbyl Palmitate
1 Trastuzumab
1 Biochanin A
1 Boron
1 Zinc
1 Capsaicin
1 Chlorophyllin
1 Citric Acid
1 Coenzyme Q10
1 Vitamin E
1 Photodynamic Therapy
1 gefitinib, erlotinib
1 Docosahexaenoic Acid
1 Ellagic acid
1 Fucoidan
1 Ferulic acid
1 Gallic acid
1 Gambogic Acid
1 Graviola
1 Grapeseed extract
1 Magnolol
1 Magnetic Field Rotating
1 Naringin
1 Niclosamide (Niclocide)
1 Oleocanthal
1 Oxygen, Hyperbaric
1 Phenylbutyrate
1 SonoDynamic Therapy UltraSound
1 Hyperthermia
1 Kaempferol
1 Salvia miltiorrhiza
1 Tomatine
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:105  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page